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Abstract
Cannabis use is associated with increased risk of psychotic symptoms and in a small number of cases 
it can lead to psychoses. This review examines the neurobiological mechanisms that mediate the link 
between cannabis use and psychosis risk. We use an established preclinical model of psychosis, the 
methylazoxymethanol acetate (MAM) rodent model, as a framework to examine if psychosis risk in 
some cannabis users is mediated by the effects of cannabis on the hippocampus, and this region’s 
role in the regulation of mesolimbic dopamine. We also examine how cannabis affects excitatory 
neurotransmission known to regulate hippocampal neural activity and output. Whilst there is clear 
evidence that cannabis/cannabinoids can affect hippocampal and medial temporal lobe function and 
structure, the evidence that cannabis/cannabinoids increase striatal dopamine function is less 
robust. There is limited evidence that cannabis use affects cortical and striatal glutamate levels, but 
there are currently too few studies to draw firm conclusions. Future work is needed to test the MAM 
model in relation to cannabis using multimodal neuroimaging approaches. 
Keywords: Cannabis, Psychosis, Schizophrenia, Hippocampus, Striatum, Dopamine, Glutamate, 
methylazoxymethanol acetate (MAM) rodent model. 
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1. Introduction
Cannabis is the most used illicit recreational drug with over 192 million users globally  (UNODC, 
2018).   The majority of cannabis users use the drug for the subjective effects that it induces; a 
feeling of getting ‘high’ or ‘stoned’ although there is now increased interest in exploring the 
medicinal use of cannabis (Grotenhermen and Müller-Vahl, 2016; Hazekamp and Heerdink, 2013; 
Isaac et al., 2016). Effects of cannabis include feelings of disinhibition or dreaminess and sensations 
of heightened awareness of music, sounds, colours or tastes (Curran et al., 2016). Experimental and 
epidemiological research suggests that cannabis use is associated with cognitive impairments (Crean 
et al., 2011; Meier et al., 2012), which may attenuate with prolonged abstinence (Scott et al., 2018), 
and an increased risk of experiencing psychotic symptoms. In a small number of cases cannabis use 
can lead to the development of psychotic disorders such as schizophrenia (Andréasson, Engström, 
Allebeck, & Rydberg, 1987; Henquet et al., 2005;  Moore et al., 2007; Zammit, 2002). 
Understanding the relationship between cannabis use and psychosis/schizophrenia is important 
because schizophrenia is a mental health disorder associated with enormous personal and societal 
cost (Chong et al., 2016; Rössler, Salize, Van Os, & Riecher-Rössler, 2005). A meta-analysis of the 
prevalence of schizophrenia shows that about 7 individuals per 1,000 is affected (McGrath et al., 
2008). As such, it represents a considerable humanistic and economic burden to society (De Silva et 
al., 2012; Millier et al., 2014). Epidemiological work indicates that an increased risk of developing 
psychotic symptoms in adulthood is associated with the early onset of cannabis use (i.e. before 15 
years of age) (Arseneault et al., 2002; Konings et al., 2008; Stefanis et al., 2004). 
In this review we aim to examine neurobiological mechanisms that may mediate the link between 
cannabis use and the experience of psychotic symptoms and/or the development of psychosis. We 
will use an established and influential animal model of psychosis, the methylazoxymethanol acetate 
(MAM) rodent model (Gomes, Rincón-Cortés, & Grace, 2016; Lisman et al., 2008; Lodge & Grace, 
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2011) as a framework to interpret studies examining the acute and chronic effects of cannabis (and 
its constituent components THC and CBD) on the human brain. Specifically, we will examine if the 
increased risk of psychotic disorders such as schizophrenia in some cannabis users is mediated by 
the effects of cannabis on the hippocampus and this region’s role in the regulation of mesolimbic 
dopamine (Lodge & Grace, 2011). We will also examine how cannabis affects concentrations of 
excitatory and inhibitory neurotransmission (i.e. effects on glutamate and GABA) that regulate 
hippocampal neural activity. Finally, we will discuss whether or not an elaboration of this MAM 
model can be extended to account for the reported relationship between cannabis use, particularly 
in adolescence, and the development of psychosis and/or psychotic like symptoms. 
2. Cannabis and how it has changed
The chemical constituents of cannabis are called cannabinoids. There are at least 140 cannabinoids 
found in the cannabis plant (Ujváry and Hanuš, 2016). Cannabis research has focused mainly on ∆9 
tetrahydrocannabinol (THC) and cannabidiol (CBD) (Pertwee, 2006). THC is the main psychoactive 
substance found in cannabis and is responsible for the subjective effects experienced by cannabis 
users (Wachtel et al., 2002). It exerts its effects by acting as a partial agonist on CB1 
endocannabinoid receptors, which are distributed across several cortical and subcortical regions 
(Herkenham et al., 1990), including the hippocampus, amygdala, striatum and cerebellum (Malone 
et al., 2010). THC is also responsible for the adverse effects associated with smoking cannabis, 
including mediating the risk of addiction (Morgan, Freeman, Schafer, & Curran, 2010), cognitive 
deficits (Oomen et al., 2018) and producing psychotic and anxiogenic effects (Morrison et al., 2009). 
CBD is the other main chemical constituent of cannabis often studied in research. This compound 
has opposing effects to THC and can ameliorate the psychotic mimicking effects of THC 
(Bhattacharyya et al., 2010; Englund et al., 2013; Morgan, 2009). For this reason it has been trialled 
as a medication for its antipsychotic (Leweke et al., 2012) and anxiolytic properties (Crippa et al., 
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2011) and has been shown to be an effective adjunct therapy in patients with schizophrenia 
(McGuire et al., 2018). There is also evidence of a restorative effect of CBD on specific sub regions of 
the hippocampus in cannabis users, most visible in heavy cannabis users (Beale et al., 2018).
At a molecular level THC and CBD differ in their actions at cannabinoid receptors. Cannabinoids are 
biosynthesized in the cannabis plant as cannabinoid acids and upon heating these acids are 
decarboxylated to their neutral forms (Kimura and Okamoto, 1970). As stated above THC is a partial 
CB1 receptor agonist. The psychomimetic effects of THC are due to its interactions with the CB1 and 
CB2 receptors in the brain (Cascio et al., 2017). Both receptors are g-protein coupled receptors that 
inhibit adenylyl cyclase and activate mitogen activated protein kinases (Pertwee, 2015). THC can act 
as both a cannabinoid receptor agonist, and antagonist, this is due to the relatively low cannabinoid 
receptor efficacy of THC; this means that its action will be dependent on the receptor densities and 
coupling efficiencies of the cannabinoid receptors (Pertwee, 2008). CB1 receptor density and efficacy 
is heterogenous and varies widely in different brain regions. THC also acts at the G-Protein couple 
receptor GPR55, with different studies reporting opposite effects (Anavi-Goffer et al., 2012; Ryberg 
et al., 2007; Yin et al., 2009). Like endogenous endocannabinoids, THC acts on presynaptic CB1 
receptors to inhibit ongoing neurotransmitter release; while the effect on the neurons which the 
receptors are present is inhibitory, this sometimes has the effect of increasing neurotransmitter 
release from neurons further downstream (Pertwee, 2008). 
CBD on the other hand acts as a low potency CB1 receptor inverse agonist and as a potent CB1
antagonist (Petitet et al., 1998). Despite a relatively low affinity of CBD at CB1 and CB2 receptors CBD 
acts at lower concentrations than the binding affinity would suggest potentially indicating activity via 
non CB1 receptor based mechanisms. It does this by acting as a CB1 receptor negative allosteric 
modulator and is able to reduce the efficacy and potency of the endocannabinoid 2-AG and of THC 
at the CB1 receptor (Laprairie et al., 2015). A number of the pharmacological actions of CBD take 
place on non-cannabinoid receptors; including the vanilloid, serotonin and GPR55 receptors 
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(Bisogno et al., 2001; Russo et al., 2005; Ryberg et al., 2007). A review by Gururajan and Malone 
demonstrates that the effects of CBD are sensitive to changes in calcium and endocannabinoid 
homeostasis (Gururajan and Malone, 2016).
FIGURE 1 HERE
There are many forms and strains of cannabis available with varying potencies, depending on the 
concentration of THC and its balance against the relative concentration of CBD within the particular 
strain (Potter et al., 2008). High potency cannabis is usually referred to as Skunk, Super Skunk or 
Sensimilla (Niesink et al., 2015). These strains have high concentrations of THC of up to 18% (Potter 
et al., 2018, 2008), showing a steady increase from the 1990’s when the average THC content of 
seized cannabis was around 6-8% (Potter et al., 2018). As well as having higher concentrations of 
THC, these newer strains of high potency cannabis, also have reduced or negligible concentrations of 
CBD (Hardwick, 2008; Potter et al. 2018). 
The other type of cannabis often found in the UK is hashish, hash or cannabis resin. Historically, 
hashish has tended to be a milder form of cannabis, with lower concentrations of THC and a more 
balanced ratio of THC and CBD (Di Forti et al., 2009). Recent research has shown that police seizures 
of hashish contain higher levels of THC than they did previously (Potter et al., 2018). This is 
significant because evidence links higher potency cannabis with increased risk of psychosis, although 
this may be specific to Skunk type cannabis (Di Forti et al., 2015, 2014). One study showed that users 
of higher potency cannabis were almost 5 times more likely to develop psychosis compared to non-
users; conversely users of low potency cannabis did not have a significantly increased risk for 
psychosis compared to non-users (Di Forti et al., 2015). Cannabis strains high in CBD may result in a 
lower risk of psychosis (Morgan & Curran, 2008; Schubart et al., 2011). 
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To summarise, the relative contents of THC and CBD in street cannabis has changed over the last few 
decades. In particular, high potency strains of cannabis such as Skunk appear to contain higher 
amounts of THC and lower amounts of CBD.  Importantly, it is these high potency strains of cannabis 
that are linked to psychosis risk.
3. The Methylazoxymethanol acetate (MAM) model of psychosis 
Psychosis covers a range of related conditions in which schizophrenia is the most common. It is 
associated with alterations in a person’s perception, thoughts, moods and behaviour to a significant 
degree (NICE, 2014). A range of neurobiological changes have been identified in people with 
schizophrenia including enlarged ventricles, volumetric reductions in the frontal lobes, thalamus and 
limbic regions including the amygdala and hippocampus (Breier et al., 1992; Honea et al., 2005; Raz 
and Raz, 1990). Two neurobiological findings that appear particularly robust are: (i) neuroanatomical 
and physiological alterations in the hippocampus and other medial temporal lobe (MTL) structures 
(Arnold, 1997; Honea et al., 2005; Karnik-Henry et al., 2012; Tamminga et al., 2010; Van Erp et al., 
2016) and (ii) elevated dopamine function in the midbrain and striatum (Brunelin et al., 2013; Howes 
et al., 2012, 2009). 
Experimental work in rodents has begun to shed light on how these factors might be linked and 
contribute to the development of psychosis. In the MAM rodent model, neurodevelopment is 
experimentally perturbed by the administration of methylazoxymethanol acetate (MAM) to 
pregnant rats on gestational day 17 (Lodge & Grace, 2011; Lodge, 2013; Moore et al. 2008, Jentsch, 
Ghajarnia, Geyer, & Grace, 2006). Work using the methylating agent MAM has highlighted the role 
of a hippocampal-midbrain-striatal circuit, and suggests that midbrain and striatal dopamine 
function is elevated as a consequence of increased neural activity in descending outputs from the 
hippocampus to the ventral striatum (Lodge & Grace, 2011). The model postulates that hyperactive 
hippocampal neural activity results in the increase in striatal dopamine in patients with 
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schizophrenia (Lodge & Grace, 2007). This increased hippocampal output indirectly increases 
presynaptic dopamine neuron activity in the ventral tegmental area (VTA) of the midbrain through 
glutamatergic and GABAergic outputs that project to the ventral striatum (nucleus accumbens) (see 
Figure 2).
FIGURE 2 HERE
Although the model is derived from animal work, there is substantial evidence in humans of altered 
hippocampal structure and function as well as elevated dopamine function in the midbrain and 
striatum in psychosis (See Modinos, Allen, Grace, & McGuire, 2015 for review). What is less clear in 
humans is how functioning of the hippocampal-midbrain circuit is perturbed in the first instance. A 
potential mechanism is altered, or imbalanced excitatory and inhibitory neurotransmission i.e. 
altered GABAergic and glutamatergic concentration in cortical and sub-cortical regions. The MAM 
model predicts increased glutamate release in the hippocampus and the striatum and reduced 
cortical GABA levels. MAM-treated rats also show altered densities in cortical GABAergic 
interneurons (Gastambide et al., 2012;  Lodge, Behrens, & Grace, 2009) which may result in the 
disinhibition of glutamatergic cells (Hammad and Wagner, 2006). This finding in rodents is broadly 
consistent with evidence that glutamate is altered in schizophrenia and psychosis risk states 
(Bossong et al., 2018; Bustillo et al., 2011; Fuente-Sandoval et al., 2011; Kraguljac, White, Reid, & 
Lahti, 2013; Merritt, Egerton, Kempton, Taylor, & McGuire, 2016; Théberge et al., 2002, 2007). 
Studies suggest that these glutamatergic changes are a result of impaired GABAergic inhibitory 
modulation (Benes & Berretta, 2001; Heckers & Konradi, 2015; Marín, 2012). Few in vivo studies 
have examined cortical GABA levels in schizophrenia and only one study has examined cortical GABA 
levels in people at risk of psychosis (Modinos et al., 2018) and reported no significant differences 
relative to healthy controls, although the sample size was small. However, a review of imaging 
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studies examining GABA and schizophrenia, reports that most studies show a reduction in GABA 
concentration in patients with schizophrenia compared to healthy controls, usually in the medial 
frontal and occipital cortices (Chiapponi et al., 2016). Post mortem studies have also reported 
GABAergic alterations in patients with schizophrenia (Benes, Kwok, Vincent, & Todtenkopf, 1998; 
Benes, Mcsparren, Bird, Sangiovanni, & Vincent, 1991; Benes & Lange, 2001).  
Whilst factors such as early stress and trauma are likely to influence the development and function 
of the hippocampal-midbrain circuit (Froudist-Walsh et al., 2017; Gomes et al., 2016),  it is also 
possible that regular cannabis use in adolescence can perturb the development and functioning of 
the hippocampal-striatal-midbrain circuit and mediates the association between early onset 
cannabis use and psychosis/psychotic like experiences (Arseneault et al., 2004). Consistent with this 
possibility, cannabinoid exposure during adolescence has been shown to exacerbate psychosis-like 
behaviours in MAM-treated rats (Gomes et al., 2015). The study also showed that pubertal 
treatment with the a CB1/2 receptor agonist in normal animals induced similar changes at adulthood 
as those observed in the MAM rats, supporting the notion that adolescence exposure to 
cannabinoids may represent a risk factor for developing psychosis-like symptoms and behaviours. It 
has also been shown that CB1 receptor mRNA levels are decreased in adolescent and adult MAM-
treated rats across a number of brain regions (Gomes et al., 2018).
In summary, the MAM model proposes that the development of psychosis is due to elevated striatal 
dopamine function that occurs as a consequence of increased neuronal activity in the hippocampus, 
possibly as a result of altered excitatory and inhibitory neurotransmission that can be affected by 
early life stress and cannabis use.  There is also evidence in experimental animals that cannabinoids, 
particularly when administered during adolescence, can affect the functioning of the hippocampal-
striatal circuit.
4. Evidence from neuroimaging studies in humans 
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4.1 Effects of cannabinoids on the hippocampus and medial temporal lobe 
Most cognitive functions seem to be impaired during acute cannabis intoxication. Impairments in 
learning and memory, as well as executive function are among the most consistently demonstrated 
effects (Bossong, Jansma, Bhattacharyya, & Ramsey, 2014; Broyd, van Hell, Beale, Yücel, & Solowij, 
2016; Cohen & Weinstein, 2018; Crean et al., 2011; Solowij & Michie, 2007). The medial temporal 
lobe (MTL) is a system of anatomically related structures including the hippocampus, perirhinal, 
entorhinal and parahippocampal cortices (Squire et al., 2004). The system plays a major role in 
learning and memory function ( Squire et al., 2004), salience detection (Bunzeck and Düzel, 2006), 
and emotional processing (Frühholz et al., 2014). Further, MTL dysfunction is linked to a number of 
pathologies including schizophrenia (Heckers, 2001; Preston et al., 2005), depression (Gorwood et 
al., 2008) and epilepsy (Spencer, 2002). Altered MTL structure and function in schizophrenia (and in 
other psychiatric conditions  – see Sprooten et al., 2017) is consistent with the marked cognitive and 
mnemonic deficits seen across different psychiatric illnesses (Karnik-Henry et al., 2012). Although 
outside the scope of this review, numerous animal studies have shown that cannabinoids impair 
performance in spatial memory tasks including a delayed non-match to position discrimination task 
(Mallet and Beninger, 1998) and a radial arm maze task (Lichtman and Martin, 1996; Varvel and 
Lichtman, 2002). Effects on memory can be reversed however, by administration of the CB1 receptor 
antagonist SR-141716A (rimonabant), indicating that effects on memory are due to action at the CB1 
receptor. Similar effects are seen in animals in which hippocampal tissue has been surgically 
removed (Hampson and Deadwyler, 1999). We will now review the experimental evidence that 
acute and chronic cannabinoid administration/use affects function and anatomy in MTL regions (for 
an extensive review of the effects of cannabis on memory see Bhattacharyya & Schoeler 2013; Jager 
et al., 2014; Bossong, Jager, Bhattacharyya, & Allen 2014).
In humans, electroencephalogram (EEG) and behavioural studies examining the acute effects of 
cannabis on working and recognition memory report reductions in item recognition based on Event 
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Related Potentials (ERP), similar to reductions seen in patients with hippocampal damage (Ilan et al., 
2004). Ilan and colleagues report similar performance deficits in casual cannabis users relative to 
non-cannabis using controls during a word recognition task, with enhanced false recognition in the 
former. Similarly, a study investigating the acute effects of THC on a number of memory 
performance measures showed that acute cannabis administration had a dose dependent effect on 
performance during an episodic memory task, without affecting perceptual priming or working 
memory (Curran, Brignell, Fletcher, Middleton, & Henry, 2002). These behavioural and ERP studies, 
along with many others (see Bhattacharyya & Schoeler, 2013 for review) suggest that cannabis is 
exerting an effect on learning and memory, and specifically episodic memory performance via the 
hippocampus/MTL. Research on the  effects of cannabis on semantic memory has proven less 
conclusive  (Morgan, Rothwell, Atkinson, Mason, & Curran, 2010; Wadsworth, Moss, Simpson, & 
Smith, 2006). This specific targeting of episodic memory further supports the notion that the effects 
of cannabis on long term memory are due to its effects on the hippocampus.
The effects of cannabis on the hippocampus are of interest because as already stated, one of the 
most robust anatomical findings in schizophrenia patients is reduced volume in hippocampus/MTL 
(Adriano et al., 2012; Honea et al., 2005). A large number of studies also report altered hippocampal 
and MTL function/perfusion in both psychosis risk states (Allen et al., 2011, 2012, 2016; Schobel et 
al., 2013; Valli et al., 2011)  and in established schizophrenia (Heckers, 2001; Tamminga et al., 2010). 
The hippocampal formation is rich in CB1 receptors (Mackie, 2005) and patients with psychosis show 
altered activation in these regions during memory tasks (Achim and Lepage, 2005; Weiss and 
Heckers, 2001). Here we will review neuroimaging studies which report the effects of both acute 
(usually defined as a single THC dose administered orally, intravenously or via a vaporizer) and 
chronic cannabis administration (naturalistic studies in regular or long-term cannabis user) on MTL 
function and structure. 
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4.1.1 Acute effects of cannabinoids on MTL function
Using functional Magnetic Resonance Imaging (fMRI) and a verbal paired associate learning task, 
Bhattacharya and colleagues showed that over subsequent encoding blocks using the same word 
pairs, there was reduced parahippocampal activation as an effect of learning in a placebo session; 
this reduced parahippocampal activation was not present after THC administration. As there was no 
significant difference in task performance between placebo and THC sessions, this suggests that THC 
results in increased or inefficient neural processing to achieve comparable levels of task 
performance (Bhattacharyya et al., 2009). Interestingly, higher hippocampal activity during the 
encoding condition of this task was associated with increased susceptibility to the psychomimetic 
effects of THC (Bhattacharyya et al., 2018). Similarly, despite the absence of differences in 
performance on the associative memory task, lower activity in the parahippocampal gyrus during 
recall of information was significantly related to a higher performance accuracy after placebo but 
not after THC administration. Together with THC-induced increases in activity in the cuneus and 
precuneus, this suggests that after THC administration, participants may engage compensatory 
mechanisms to maintain task performance (Bossong et al., 2012).
Bhattacharyya and colleagues also used an oddball task to examine the acute effects of THC and CBD 
on salience processing.  They showed that THC and CBD had opposing effects on activity in the 
hippocampus and parahippocampal gyrus, with attenuated activity after THC and augmented 
activity after CBD compared to placebo. Whereas hippocampal activation was attenuated by THC, it 
was augmented after single CBD administration. These observations suggest that elevated MTL 
activity is involved in the acute increase of aberrant attribution of salience after THC administration  
(Bhattacharyya et al., 2012). 
Finally, during processing of facial expressions of emotions, activity in the hippocampus was reduced 
after THC administration with processing of positive stimuli (happy faces) but increased with 
processing of negative stimuli (fearful faces). This suggests that administration of THC shifts the 
13
brain's bias for stimuli that have a negative impact towards a bias for stimuli that have a positive 
impact (Bossong et al., 2013). 
Overall, although few studies have been conducted, it has been shown that acute THC 
administration affects MTL activity and that THC and CBD may have opposing effects on MTL 
function during the performance of different types of cognitive paradigms.  
4.1.2 Chronic effects of cannabis on MTL function 
One of the earliest neuroimaging studies to examine the long-term effects of cannabis use on the 
MTL was conducted by Block and colleagues using [150] water-PET to examine the effects of regional 
cerebral blood flow (a proxy of neural activation) during a range of memory tasks. This study found 
altered hippocampal lateralisation in cannabis users i.e. the left hippocampus was more active than 
the right during memory tasks in regular cannabis users relative to a non-cannabis using control 
group (Block et al., 2002). Using fMRI it has also been shown that regular cannabis users show 
reduced bilateral hippocampal activation relative to non-cannabis users during the encoding phase 
of an associative learning task, despite no significant difference between groups on task 
performance (Jager et al., 2007). Nestor and colleagues also conducted an fMRI study with an 
associative learning task that activates hippocampal regions. Whole brain analysis revealed that the 
cannabis user group had significantly lower activity during the learning phase of the task than the 
non-cannabis using control group in a number of cortical regions. However, region of Interest 
analysis of hippocampal and parahippocampal regions showed that the cannabis group had 
significantly greater activity in the right parahippocampal gyrus during learning (Nestor et al., 2008). 
Increased parahippocampal activation is the opposite of what was seen in the Jager study discussed 
above (Jager et al., 2007). Whilst there was no significant difference in task performance, the 
differences in hippocampal activation between the two studies could be because the associative 
memory task used by Nestor and colleagues was harder, requiring participants to match pictures to 
numbers as opposed to matching two pictures, as was the case in the Jager study. 
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Although findings are equivocal (Scott et al., 2018) it has been reported that regular cannabis use in 
adolescence can increase the deleterious effects of the drug on cognitive function (Meier et al., 
2012) and increase risk for psychosis in adulthood (Arseneault et al., 2004, 2002). To examine the 
effects of regular cannabis use in adolescence, Jacobsen and colleagues used fMRI in combination 
with a verbal memory task in 7 abstinent adolescent cannabis users, age matched tobacco smokers 
and non-smokers. During the memory task, performance accuracy of cannabis users was significantly 
lower than that of both tobacco smokers and non-smokers. Region of interest analysis revealed that 
cannabis users failed to deactivate the right hippocampus across working memory task conditions, 
as opposed to both control groups (Jacobsen et al., 2004). These findings suggest that adolescent 
cannabis users may have disrupted neural activity when task-focused attention is required, resulting 
in impaired task performance. However, findings from this study should be interpreted cautiously as 
the sample size was small and the functional task used did not directly test episodic memory/verbal 
learning. Furthermore, Jager et al. (2010) report that adolescent cannabis users showed no 
differences in hippocampal activation during an associative memory task relative to adolescent non-
cannabis users. 
In summary, there appears to be some evidence for long-term effects of cannabis use on 
hippocampal/MTL function, but interpretations are hampered by differences in cannabis types and 
demographic factors such as lifetime cannabis use and abstinence time. There appears to be no 
particular evidence for stronger effects of adolescent cannabis use on MTL function. 
4.1.3 Chronic effects of cannabis on MTL structure
A number of volumetric studies have examined the effects of chronic cannabis use on hippocampal 
and MTL structure. Preclinical studies have established that THC is toxic to cultured hippocampal 
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neurons, and that this is mediated through CB1 receptors, with CA1 pyramidal neurons being 
particularly sensitive (Chan et al., 1998; Lawston et al., 2000). Yucel and colleagues (2008) 
investigated if long-term heavy cannabis use was associated with anatomical abnormalities in the 
hippocampus and the amygdala. Long-term cannabis users showed bilaterally reduced hippocampal 
and amygdala volumes. Furthermore, left hemisphere hippocampal volume was inversely associated 
with cumulative exposure to cannabis during the previous 10 years. Psychotic symptom scores 
(hallucinations and delusions) were also associated with cumulative exposure to cannabis.
 Although cannabis users showed performance deficits relative to controls on a verbal learning task, 
performance was not related to regional brain volumes in either group. Lorenzetti et al. (2015) 
report that heavy cannabis users show smaller hippocampus and amygdala volumes but no 
alterations of the orbitofrontal and para-cingulate cortices, indicating that chronic cannabis use has 
a selective and detrimental impact on the morphology of the MTL. Battistella and colleagues (2014) 
report that regular cannabis use is associated with grey matter volume reduction in the MTL, 
temporal pole, parahippocampal gyrus, insula and orbitofrontal cortex, regions rich in CB1 receptors 
and functionally associated with motivational, emotional and affective processing. They also report 
that the age of onset of regular cannabis use influences the magnitude of these volumetric changes.  
Ashtari and colleagues (2011) report that heavy cannabis users show smaller bilateral hippocampal 
volume but not amygdala volumes compared to controls. In controls, larger hippocampal volumes 
were significantly correlated with higher verbal learning and memory scores, but these relationships 
were not observed in cannabis users. These findings in heavy cannabis users, after an average 6.7 
months of supervised abstinence, lend support to the idea that cannabis use may impart long-term 
structural damage to the hippocampus. Alternatively, the observed hippocampal volumetric 
abnormalities may represent a risk factor for cannabis dependence. Demirakca and colleagues 
(2011) report similar hippocampal volumetric findings to those reported above but in addition they 
report that reduced right hippocampal volume in regular cannabis users is associated with the ratio 
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of THC/CBD in the cannabis being used by their participants. It must be noted however that there 
are a range of factors other than cannabis use that can play a role in hippocampal damage. For 
example, a number of environmental risk factors, in particular stress in early life (Paquola et al., 
2016) can result in reduced hippocampal volume,  increased psychosocial stress (Paus et al., 2008) 
and increased risk  for schizophrenia (Mizrahi et al., 2014). Indeed, stress has been linked to 
hippocampal damage that may precede cannabis use  (Modelli et al., 2010,2011). Such confounding 
factors should be taken into account when considering the relationship between cannabis and 
hippocampal function and volume. 
 
To summarise, several studies have linked regular cannabis use to reduced volume in the 
hippocampus and other MTL regions. However, there is no clear link between cannabis related 
volumetric reduction in the MTL, cognition, and psychosis like experiences/psychosis risk.  It should 
be noted that some volumetric studies have failed to find differences in hippocampal volume in 
cannabis users compared to non-cannabis using controls. Studies by Block et al. (2000)  and Tzilos et 
al. (2005) both found no significant difference in hippocampal volume between cannabis users and 
controls. Using a region of interest approach, Cousijn et al. (2012) found larger bilateral anterior 
lobes in the cerebellum of cannabis users but no significant differences in the hippocampus or 
amygdala in heavy cannabis users compared to non-cannabis users. It is possible that mixed results 
reported by volumetric studies are due to confounders such as lifetime cannabis use, abstinence 
time and use of other illicit drugs (see Bossong et al., 2014).  
4.2 Cannabinoids, striatal function and dopamine 
4.2.1 Acute Studies 
It is widely established that schizophrenia and psychosis risk states are associated with aberrant 
striatal neural activity (Fusar-Poli et al., 2011) and increased presynaptic striatal dopamine levels 
(Howes et al., 2012). There are far fewer studies investigating striatal activity and striatal dopamine 
levels in relation to cannabis use/cannabinoid administration. A case study by Vorungati and 
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colleagues was the first to identify an increase in striatal dopamine activity following cannabis use. A 
drug-free patient with schizophrenia took part in a SPECT (single photon emission computed 
tomography) study and during a break in the scanning protocol, surreptitiously smoked a cannabis 
cigarette. The cannabis use led to worsening of psychotic symptoms a few hours later and to a 20% 
decrease in striatal D2 receptor binding measured on the scan following the break. This suggested an 
increase in striatal dopamine release following cannabis use, and a role for striatal dopamine in the 
consequent worsening of psychotic symptoms (Voruganti et al., 2001). 
Using Positron Emission Tomography (PET) and the dopamine D2/D3 receptor tracer [11C]-raclopride 
in healthy participants, Bossong and colleagues found that following administration of inhaled THC, 
purified from cannabis, there was a significant reduction in [11C]-raclopride binding, indicating an 
increase in dopamine levels, in the ventral striatum and precommisural dorsal putamen compared to 
placebo (Bossong et al., 2009). This was a small study, but it was the first group study to show that 
THC induced elevated striatal dopamine release. In contrast, another study using the same 
methodology ([11C]-raclopride PET) found no significant effect of oral THC on dopamine release in 
the striatum relative to placebo in healthy volunteers (Stokes et al., 2009). In a reanalysis of the 
pooled PET data from the aforementioned studies (i.e. Bossong et al., 2009; Stokes et al., 2009), 
Bossong and colleagues confirmed the moderate but significant reduction in [11C]-raclopride binding 
in the ventral striatum (Bossong et al., 2015). Because of this modest effect (-3.65%), the authors 
concluded that an increase in striatal dopamine was unlikely to be the primary driver of the 
increased risk of schizophrenia in cannabis users. Moreover, an independent SPECT study by Barkus 
and colleagues that administered THC intravenously failed to induce any significant elevations in 
striatal dopamine release (Barkus et al., 2011). 
A study by Kuepper and colleagues examined the effects of THC administration on striatal dopamine 
release in patients with a psychotic disorder, unaffected relatives and healthy controls. This PET 
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study administered THC extracted from the cannabis plant via inhalation and measured dopamine 
release by assessing D2 receptor binding using 18FFallypride (Kuepper et al., 2013). The study reports 
that the amount of striatal dopamine release was dependent on participants’ risk of psychosis, with 
patients with psychotic disorder and their relatives releasing significantly more dopamine in 
response to THC than healthy controls, with the biggest difference in the left caudate nucleus. 
 Functional MRI studies have also shown that the acute administration of THC can affect task-related 
striatal activation. Bhattacharyya reports that during a paired-associated verbal memory task (also 
discussed above), THC attenuated the normal linear decrement seen in the striatum after repeated 
encoding blocks relative to a placebo condition (Bhattacharyya et al., 2009). In the same study 
cohort THC induced decreases in striatal activity reported during an oddball task (Bhattacharyya et 
al., 2012), an effect that was reversed by the administration of CBD (Bhattacharyya et al., 2010). 
Moreover, the effect of THC in the striatum was inversely correlated with the severity of the 
psychotic symptoms. 
In a further exploration of their previous fMRI study with acute THC administration and a verbal 
associative learning paradigm (in an increased sample), Bhattacharyya et al. (2012b) showed that in 
healthy volunteers the effects of THC on both behaviour and brain activity were affected by 
variation in the genes for the dopamine transporter (DAT1, which removes dopamine from central 
synapses) and the protein kinase B (AKT1, an integral component of the dopamine signalling 
cascade). Carriers of polymorphisms associated with higher dopamine neurotransmission showed an 
increased sensitivity to the psychotic effects of THC and to activity in both the striatum during 
encoding and midbrain during recall (Bhattacharyya et al., 2012b). Reward processing paradigms 
have also been used to assess acute THC effects on striatal activity, with increased striatal response 
during reward anticipation after THC compared to placebo in some studies (Jansma et al., 2013) and 
an absence of THC effects on striatal activity in others (van Hell et al., 2012). 
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In summary, acute administration studies using PET and fMRI imaging provide evidence for the acute 
effects of THC on dopamine and striatal function. However, the effects sizes may be small and fMRI 
studies have provided some equivocal findings. It is possible that the effects of acute THC 
administration on dopamine and striatal function depend to some extent on the genetic profile for 
dopamine signaling. 
4.2.2 Chronic Studies
Acute studies examining dopamine release have assessed the effects of a single THC administration 
on dopamine release/striatal activity compared to a placebo condition. PET studies in chronic 
cannabis users can examine the effect of heavy cannabis use on dopamine release following a 
stimulant challenge known to cause striatal dopamine release. 
Using [11C] raclopride, Volkow and colleagues compared regular cannabis users to non-cannabis 
using controls to assess striatal dopamine release following a methylphenidate challenge (known to 
increase extracellular dopamine). The study reports that regular cannabis users showed a significant 
difference in [11C] raclopride binding in the striatum compared to controls, which suggests a blunted 
response to methylphenidate. The study concludes that the attenuated response to 
methylphenidate in regular cannabis users is consistent with decreased brain reactivity to dopamine 
stimulation that might contribute to negative emotionality and addictive behaviours in cannabis 
users (Volkow et al., 2014). 
Bloomfield and colleagues assessed dopamine synthesis capacity using [18F]-DOPA in cannabis users 
and non-cannabis using controls (Bloomfield et al., 2014). This study reports that striatal dopamine 
synthesis capacity was lower in cannabis users compared to controls. This was particularly 
prominent in subjects that were heavy cannabis users. Van de Giessen and colleagues ( 2017) also 
looked at the effects of heavy cannabis use on striatal dopamine release following an amphetamine 
challenge. The study assessed heavy cannabis users and non-cannabis using controls in a PET study 
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using a more sensitive D2/3 agonist radiotracer [11C] –(+)-PHNO. Similar to findings from the Volkow 
(2014) study, a deficit in striatal dopamine release (caudate) was seen in cannabis users  compared 
to controls following a stimulant challenge. Consistent with this view, using PET, Leroy and 
colleagues measured striatal and extra striatal dopamine transporter (DAT) availability (Leroy et al., 
2012). DAT availability in the dorsal striatum was significantly reduced in regular cannabis users 
relative to non-cannabis using controls. One study however, using PET and [11C] raclopride in regular 
cannabis users reported no changes in striatal dopamine function after amphetamine challenge 
(Urban et al., 2012). 
In summary, findings in chronic users suggest that regular cannabis use is associated with lower 
striatal dopamine synthesis and reductions in dopamine release. Taken together with the findings 
from acute administration studies, which suggest the THC may only induce small effects on striatal 
dopamine, it is possible that the association between cannabis use and psychosis is not entirely due 
to an increase in striatal dopamine release. It is worth noting however that across the schizophrenia 
literature PET studies that examined [11C] and [18F]-DOPA have also reported conflicting results. This 
may be because PET and SPECT studies using receptor tracers such as  [11C]-raclopride and studies 
using [18F]-DOPA are measuring dopamine function at post and pre synaptic locations respectively. 
Furthermore, a number of confounding factors such as antipsychotic medication and illness stage 
may also affect the findings of PET studies measuring dopamine function in schizophrenia patients. 
Thus the prediction that the link between cannabis use and psychosis is mediated by increased 
striatal dopamine function may be simplistic.  Finally, it should be considered that genetic factors 
and environmental factors such as stress (Egerton et al., 2016)  known to increase risk for substance 
use and psychosis (Howes et al., 2017) have also been shown to blunt dopamine release to 
amphetamine challenge (Casey et al., 2014). This raises the possibility that the blunted dopamine 
response seen in cannabis users may precede cannabis use rather than be a consequence.
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5. Cannabis, Glutamate and GABA
The MAM model of psychosis proposes that changes to cortical GABAergic and glutamatergic 
neurotransmission results in increased hippocampal neural activity and dysfunction of the 
hippocampal-midbrain circuit (Moore et al., 2006).  It is possible that the acute and chronic effects of 
cannabis/cannabinoids on hippocampal function and volume are mediated by cannabis-induced 
changes in excitatory and inhibitory neurotransmitter function. Indeed, the main role of the 
endocannabinoid system is to regulate excitatory and inhibitory neurotransmission (Wilson and 
Nicoll, 2002). The CB1 receptor is the most abundant G-protein-coupled receptor in the central 
nervous system (Cabral et al., 2008; Pertwee, 2006). The two most important endocannabinoid 
ligands binding to endocannabinoid receptors are anandamide and 2-arachidonylglycerol, which act 
as retrograde messengers. They are synthesized and released postsynaptically and bind to 
presynaptic receptors, thereby regulating the release of both inhibitory and excitatory 
neurotransmitters. This signalling works according to an ‘on demand’ principle: endocannabinoids 
are released when and where they are needed (Kano et al., 2009; Katona and Freund, 2012).
Research using both preclinical in-vitro and in-vivo models shows that THC depresses 
endocannabinoid mediated glutamate synaptic transmission. This affects glutamate release, enzyme 
activity and also the expression of receptors and transports (for review see Colizzi, McGuire, 
Pertwee, & Bhattacharyya 2016).  At present, there are only a handful of in-vivo studies that 
examine the effects of cannabis on glutamate function and no studies that look at the effect of 
cannabis on GABAergic functioning. 
Using Magnetic Resonance Spectroscopy (1H-MRS), Chang and colleagues (2006), examined the 
effects of regular cannabis use in HIV positive patients and healthy controls on brain metabolites. 
The study found that glutamate metabolite levels in the basal ganglia were reduced in cannabis 
users relative to non-cannabis user controls. This reduction was seen in a HIV negative group but 
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was most prominent when both the HIV positive and negative cannabis user groups were analysed 
together with a 12-13% decrease in basal ganglia glutamate levels. 
Muetzel et al. (2013) examined a similar striatal region in heavy cannabis users and non-cannabis 
using controls. When the whole group was assessed there was a non-significant reduction in striatal 
glutamate metabolites. However, the study found sex differences such that there was a significant 
reduction in striatal glutamate metabolites in the female cannabis users compared to female 
controls. It should be noted that in this study the outcome measure was glutamate + glutamine 
metabolites (Glx) combined as opposed to just glutamate.
Prescot and colleagues (2011) examined the effects of chronic cannabis use on metabolites in the 
anterior cingulate cortex of adolescent cannabis users. Using 1H-MRS at 3T they found significant 
reductions in glutamate metabolites in the ACC in regular cannabis users compared to non-users. 
The same group carried out another similar study examining the same voxel, comparing an 
independent cohort of adolescent cannabis users to age-matched non-users. In the second study 
Prescot and colleagues again reported significantly lower ACC glutamate and GABA concentrations in 
cannabis users compared to controls (Prescot et al., 2013). Sung and colleagues also used 1H-MRS to 
examine the effects of regular cannabis use on ACC metabolite levels. However, this group tested 
concomitant cannabis and methamphetamine users. This study did not find significant difference in 
glutamate+glutamine metabolites between the users and non-drug using controls in the ACC. It 
should be noted that this study had quite a small sample size and this may have resulted in the lack 
of a significant finding (Sung et al., 2013).
Recently however, one study has directly examined the acute effects of THC administration on 
striatal glutamate levels (Collizi et al. 2019). Compared to placebo, acute administration of THC 
significantly increased Glx (Combined Glutamine metabolites) in the left caudate head. Furthermore, 
compared to individuals who were not sensitive to the psychotomimetic effects of THC, individuals 
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who developed transient psychotic-like symptoms had significantly lower baseline Glx levels. These 
results show that THC can increase striatal glutamate levels and that lower baseline levels of striatal 
glutamate metabolites may be a marker of greater sensitivity to its acute psychotomimetic effects.
On a molecular level, the main role of the endocannabinoid system is to regulate synaptic activity via 
glutamate and GABA-ergic transmission (Wilson and Nicoll, 2002). This is achieved by retrograde 
inhibition of both GABA-ergic and glutamatergic synapses throughout the brain (Chevaleyre et al., 
2006; Marsicano et al., 2003; Schlicker and Kathmann, 2001). Endocannabinoids only affect 
neurotransmitter release from their accompanying presynaptic site, allowing for protection against 
excessive glutamate receptor stimulation. However, external cannabinoids may affect the normal 
endocannabinoid regulatory system by downregulation and desensitization of CB1 receptors 
(Bossong and Niesink, 2010). These effects have been shown after chronic administration of 
synthetic cannabinoid agonists and THC (Breivogel et al., 1999; Sim-Selley and Martin, 2002). 
Disruption of normal endocannabinoid homeostasis of Glutamate and GABA by exogenous 
endocannabinoids could then result in the differences in these metabolite concentrations in 
cannabis users. However, as discussed previously, environmental factors such as stress and early life 
trauma can also perturb glutamate and GABAergic function (Allen et al., 2019), factors that may also 
increase risk of chronic cannabis use in later life (Schlossarek et al., 2016).
To summarise, the MRS data in regular cannabis users points towards reduced glutamate levels in 
striatal and cortical regions. However, there are currently too few studies to draw any firm 
conclusions about the effect of cannabis use on brain glutamate levels although one acute study 
does provide evidence of a link between exposure to THC, striatal glutamate levels and psychosis 
proneness. To date, there have been no studies that have explicitly examined GABA levels in 
cannabis users and no studies have utilised an ‘acute challenge’ design. 
6. Discussion & Future work
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Using the MAM rodent model as a heuristic framework, in this review we aimed to examine if 
altered neurobiological functioning in a hippocampal – striatal – midbrain circuit, which regulates 
mesolimbic dopamine function, mediates the link between cannabis use and the experience of 
psychotic symptoms and/or increased risk for psychosis.  Overall, studies examining the effects of 
acute THC administration on hippocampal and MTL function indicate that THC can affect 
hippocampal activation during memory and salience tasks (Bhattacharyya et al., 2009; Sagnik 
Bhattacharyya et al., 2012) and that increased hippocampal and parahippocampal activity is 
associated with a susceptibility to the psychotic effects of THC (Atakan et al., 2013; Bhattacharyya et 
al., 2018). However, studies have reported both increased and decreased hippocampal/MTL activity 
after acute THC administration. The subtraction methods used in task related fMRI studies 
(experimental vs. control condition) make these functional findings difficult to interpret. Easier to 
understand are perfusion and volumetric studies in chronic cannabis users which have reported 
increased parahippocampal perfusion and reduced hippocampal volume, findings broadly consistent 
with the MAM rodent model. Furthermore, studies examining the effect of cannabis and 
cannabinoids on MTL function and volume implicate a number of different MTL regions i.e. posterior 
and anterior hippocampus and the parahippocampal gyrus. The MAM rodent model however posits 
that neural hyperactivity is seen in the anterior hippocampus (analogous to the CA1 in humans). This 
is consistent with human studies in a psychosis risk cohort that report elevated hippocampal 
perfusion in the CA1 and subiculum subfields of the hippocampus (Schobel et al., 2013).  However, 
the effects of cannabis/THC on hippocampal function and volume appear to be more widespread.  
This observation may be due to the differential effects of acute and chronic cannabinoid 
administration on the MTL and differences in study designs used to assess these effects.  It should 
also be noted that studies in chronic cannabis users do not take into account the effects of CBD on 
brain activity. It has been shown that CBD and THC have opposing effects on brain activity in several 
regions including the hippocampus (Bhattacharyya et al., 2010). This may be one reason that the 
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findings from the chronic studies are more equivocal, with chronic cannabis users consuming a range 
of different cannabis types with differing levels of THC and CBD. 
PET studies examining the effects of acute THC administration on striatal D2 receptor binding 
suggest that THC can increase striatal dopamine function, albeit with a moderate effect size. Studies 
in chronic users tend to show that cannabis blunts striatal dopamine response compared to non-
cannabis using controls. This blunted response could be due to a down regulation of dopamine 
transporter as seen in other studies (Leroy et al., 2012).  fMRI studies have shown an acute impact of 
THC on striatal activity patterns during paradigms involving learning, reward anticipation and 
salience processing, with some of these effects depending on genetic profile for dopamine signalling 
(Bhattacharyya et al., 2012). Taken together, and broadly in line with the MAM rodent model, the 
findings from PET and fMRI studies suggest that cannabis can affect dopamine and striatal function 
both in acute administration studies and in chronic users.  However, the pattern is complex given the 
findings of blunted dopamine response in chronic cannabis users. Again, how these findings align 
with the MAM rodent model of psychosis is difficult to assess. It is possible that, consistent with the 
MAM model, cannabis initially increases striatal dopamine function and that the longer-term 
cannabis use causes a blunting of the dopamine function through adaptive mechanisms. 
Finally, very few studies have examined how cannabinoids affect cortical and subcortical glutamate 
levels. Overall, there appears to be some evidence that cannabis use alters glutamate 
concentrations in striatum and ACC but there is no evidence for increased glutamate concentrations 
in the hippocampus, as would be predicted by the MAM rodent model. However, a recent MRS 
study reports that acute THC administration increases striatal Glx levels that were initially lower in 
subjects more sensitive to the psychosis inducing effects of THC. No studies have examined the 
effects of cannabinoids on cortical GABA concentrations. 
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Together, the available evidence provides some support for the notion that the relationship 
between cannabis use and psychosis risk is mediated through altered hippocampal function, striatal 
dopamine and glutamate levels. However, much more work is needed to test the predictions of the 
MAM rodent model systematically in humans and there are a number of environmental factors that 
may confound this relationship. No studies have examined the effects of cannabis, acutely or 
chronically, on GABA levels. Regarding cannabis use during adolescence, a recent rodent study 
reports that adolescent synthetic cannabinoid exposure significantly increased the proportion of 
susceptible rats displaying a schizophrenia-like hyperdopaminergic phenotype and that this acquired 
phenotype appears to correspond with alterations in parvalbumin GABAergic interneuron function 
within the hippocampus (Aguilar et al., 2018). Whilst more animal work is needed to understand the 
precise mechanisms through which cannabinoids act upon the hippocampal-striatal-midbrain circuit, 
the findings by Aguilar and colleagues are in line with epidemiological studies in humans that 
suggest adolescent exposure to cannabis increases risk for psychosis (Arseneault et al., 2002). 
To conclude, whilst cannabis and THC clearly affect hippocampal function and structure 
(chronically), we cannot firmly conclude that these effects are driving the increased risk of psychosis 
via changes in striatal dopamine function. There is limited evidence that cannabis affects cortical and 
subcortical glutamate levels. Future work should apply multi-modal neuroimaging approaches that 
examine the relationship between hippocampal function/volume, striatal dopamine function and 
cortical and subcortical glutamate and GABA concentrations in order to establish the systematic 
effects of cannabis/THC on the functioning of the hippocampal-striatal-midbrain circuit. 
Furthermore, given the increased use of synthetic cannabinoids (Cohen and Weinstein, 2018b) it 
may also be interesting to examine the effects of  synthetic cannabinoids e.g. ‘Spice’ on dopamine, 
glutamate, hippocampal and striatal function. This is outside the scope of the current review but it is 
known that synthetic cannabinoids contain CB1 and CB2 receptor agonists, but do not contain CBD 
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(Martinotti et al., 2017). Worryingly studies have found that synthetic cannabinoids result in more 
severe clinical outcomes including hallucinations (Forrester et al., 2012).
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Figure 1: Chemical structures of Tetrahydrocannabinol (THC) and Cannabidiol (CBD)
Figure 2: Diagram showing hippocampal- midbrain- striatal circuit involved in the regulation of striatal 
dopamine/activity. In psychosis dysregulation of glutamate (due to glutamate/GABAergic imbalances) elevates 
hippocampal neural activity (hyperperfusion) (A) and output (B, blue line), which alters hippocampal function. 
Hippocampal hyperactivity leads to increased striatal/dopamine function (C & D, dashed and red lines). 
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